Sexual dysfunction in multiple sclerosis: The impact of different MSISQ-19 cut-offs on prevalence and associated risk factors.

Cognition MSISQ-19 Multiple sclerosis Outcome measurement Quality of life Sexual dysfunction

Journal

Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247

Informations de publication

Date de publication:
Oct 2023
Historique:
received: 03 10 2022
revised: 14 07 2023
accepted: 21 07 2023
pubmed: 31 7 2023
medline: 31 7 2023
entrez: 31 7 2023
Statut: ppublish

Résumé

Although multiple sclerosis (MS) Intimacy and Sexuality Questionnaire-19 (MSISQ-19) is a widely applied tool, no unique definition of sexual dysfunction (SD) based on its score exists. To explore the impact of different MSISQ-19 cut-offs on SD prevalence and associated risk factors, providing relevant information for its application in research and clinical settings. After defining SD according to two different MSISQ-19 cut-offs in 1155 people with MS (pwMS), we evaluated SD prevalence and association with sociodemographic and clinical features, mood status and disability via logistic regression. Depending on the chosen cut-off, 45% to 54% of pwMS reported SD. SD defined as MSISQ-19 score >30 was predicted by age (OR=1.01, p=0.047), cognition (OR=0.96, p=0.004) and anxiety (OR=1.03, p=0.019). SD defined as a score >3 on any MSISQ-19 item was predicted by motor disability (OR=1.12, p=0.003) and cognition (OR= 0.96, p=0.002). Applying different MSISQ-19 cut-offs influences both the estimated prevalence and the identification of risk factors for SD, a finding that should be considered during study planning and data interpretation. Preserved cognition exerts a protective effect towards SD regardless from the specific study setting, representing a key point for the implementation of preventive and therapeutic strategies.

Sections du résumé

BACKGROUND BACKGROUND
Although multiple sclerosis (MS) Intimacy and Sexuality Questionnaire-19 (MSISQ-19) is a widely applied tool, no unique definition of sexual dysfunction (SD) based on its score exists.
OBJECTIVE OBJECTIVE
To explore the impact of different MSISQ-19 cut-offs on SD prevalence and associated risk factors, providing relevant information for its application in research and clinical settings.
METHODS METHODS
After defining SD according to two different MSISQ-19 cut-offs in 1155 people with MS (pwMS), we evaluated SD prevalence and association with sociodemographic and clinical features, mood status and disability via logistic regression.
RESULTS RESULTS
Depending on the chosen cut-off, 45% to 54% of pwMS reported SD. SD defined as MSISQ-19 score >30 was predicted by age (OR=1.01, p=0.047), cognition (OR=0.96, p=0.004) and anxiety (OR=1.03, p=0.019). SD defined as a score >3 on any MSISQ-19 item was predicted by motor disability (OR=1.12, p=0.003) and cognition (OR= 0.96, p=0.002).
CONCLUSION CONCLUSIONS
Applying different MSISQ-19 cut-offs influences both the estimated prevalence and the identification of risk factors for SD, a finding that should be considered during study planning and data interpretation. Preserved cognition exerts a protective effect towards SD regardless from the specific study setting, representing a key point for the implementation of preventive and therapeutic strategies.

Identifiants

DOI: 10.1016/j.msard.2023.104907 PMID: 37523809
pubmed: 37523809
pii: S2211-0348(23)00408-X
doi: 10.1016/j.msard.2023.104907
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

104907

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest MP discloses travel/meeting expenses from Novartis, Roche and Merck, speaking honoraria from HEALTH&LIFE S.r.l., honoraria for consulting services from Biogen and research grants from Baroni Foundation. A. Carotenuto has received research grants from ALMIRALL, and honoraria from Novartis, Merck and Biogen. M. Moccia has received research grants from the ECTRIMS-MAGNIMS, the UK MS Society, and Merck, and honoraria from Biogen, Merck, Novartis and Roche. S. Bucello has served on scientific advisory boards for Biogen Idec, Roche, Merck Serono, Novartis, Celgene and Sanofi-Genzyme and has received funding for travel and/or speaker honoraria from Sanofi-Genzyme, Biogen Idec, Teva, Merck Serono and Novartis. MI received compensation for consulting services and/or speaking activities from Biogen Idec, Merck-Serono, Novartis, Roche, Sanofi Genzyme; received research support from NIH, NMSS, the MS Society of Canada, the Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, H2020 EU Call. M. Clerico received personal compensations for advisory boards, public speaking, editorial commitments or travel grants from Biogen Idec, Merck Serono, Fondazione Serono, Novartis, Roche, Sanofi-Genzyme and Teva. LM received personal compensations for speaking in scientific meeting and for advisory boards and for travel grants from Celgene, Novartis, Biogen, Merck, Roche and Sanofi. LL received speaker honoraria and travel grants from Teva, Merck, Sanofi, Novartis, Biogen, Roche and Bayer. MF is Editor-in-Chief of the Journal of Neurology, has received compensation for consulting services and/ or speaking activities from Biogen Idec, Merck-Serono, Novartis, Teva Pharmaceutical Industries, and receives research support from Biogen Idec, Merck-Serono, Novartis, Teva Pharmaceutical Industries, Roche, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla and ARiSLA (Fondazione Italiana di Ricerca per la SLA). GB received fees for consultation and Advisory board from Biogen, Almirall, Novartis, Merck, Teva, Roche and Sanofi Genzyme. CP received consulting and lecture fees and research funding and travel grants from Almirall, Bayer, Biogen, Gen- zyme, Merck Serono, Novartis, Roche and Teva. VBM has received research grants from the Italian MS Society, and Roche, and honoraria from Bayer, Biogen, Merck, Mylan, Novartis, Roche, Sanofi-Genzyme, and Teva. RL has received honoraria from Biogen, Merck, Novartis, Roche, and Teva. Other authors have nothing to disclose.

Auteurs

M Petracca (M)

Department of Neurosciences and Reproductive and Odontostomatological Sciences, University of Naples Federico II, Via Pansini 5, Naples 810145, Italy.

A Carotenuto (A)

Department of Neurosciences and Reproductive and Odontostomatological Sciences, University of Naples Federico II, Via Pansini 5, Naples 810145, Italy.

C Scandurra (C)

Department of Neurosciences and Reproductive and Odontostomatological Sciences, University of Naples Federico II, Via Pansini 5, Naples 810145, Italy.

M Moccia (M)

Department of Molecular Medicine and Medical Biotechnology, Federico II University of Naples, Italy; MS Unit, Federico II University Hospital, Naples, Italy.

L Rosa (L)

Department of Public Health, University of Naples Federico II, Naples, Italy.

S Arena (S)

Department "G.F. Ingrassia", MS Center, University of Catania, Catania, Italy.

A Ianniello (A)

MS Center, S. Andrea Hospital, Sapienza University of Rome, Rome, Italy.

A Nozzolillo (A)

Multiple Sclerosis Center, Neurology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.

M Turrini (M)

Centro Sclerosi Multipla, ASST Spedali Civili di Brescia, Ospedale di Montichiari, Brescia, Italy.

L M Streito (LM)

San Luigi Gonzaga Academic Hospital, Orbassano, TO 10043, Italy.

G Abbadessa (G)

Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.

M Cellerino (M)

Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Genoa, Italy.

S Bucello (S)

Multiple Sclerosis Centre, "E. Muscatello" Hospital - ASP8, Augusta, SR, Italy.

E Ferraro (E)

S. Filippo Neri Hospital, Rome, Italy.

M Mattioli (M)

NCL-Istituto di Neuroscienze Gruppo Neuromed, Rome, Italy.

A Chiodi (A)

Intradepartmental Program of Clinical Psychology, Federico II University Hospital, Naples, Italy.

M Inglese (M)

Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Genoa, Italy; IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

S Bonavita (S)

Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.

M Clerico (M)

San Luigi Gonzaga Academic Hospital, Orbassano, TO 10043, Italy; Department of Clinical and Biological Sciences, University of Torino, Torino 10128, Italy.

C Cordioli (C)

Centro Sclerosi Multipla, ASST Spedali Civili di Brescia, Ospedale di Montichiari, Brescia, Italy.

L Moiola (L)

Multiple Sclerosis Center, Neurology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.

F Patti (F)

Department "G.F. Ingrassia", MS Center, University of Catania, Catania, Italy.

L Lavorgna (L)

Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.

M Filippi (M)

Multiple Sclerosis Center, Neurology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy.

G Borriello (G)

MS Center, San Pietro Hospital Fatebenefratelli, Rome, Italy.

E D'Amico (E)

Department "G.F. Ingrassia", MS Center, University of Catania, Catania, Italy.

C Pozzilli (C)

Department of Human Neurosciences, Sapienza University, Rome, Italy.

V Brescia Morra (V)

Department of Neurosciences and Reproductive and Odontostomatological Sciences, University of Naples Federico II, Via Pansini 5, Naples 810145, Italy.

R Lanzillo (R)

Department of Neurosciences and Reproductive and Odontostomatological Sciences, University of Naples Federico II, Via Pansini 5, Naples 810145, Italy. Electronic address: roberta.lanzillo@unina.it.

Classifications MeSH